Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

CCNG2 expression is downregulated in colorectal carcinoma and its clinical significance

verfasst von: G. G. Sun, J. Zhang, W. N. Hu

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to analyze the expression, clinical significance of cyclin G2 (CCNG2) in colorectal carcinoma, and the biological effect in its cell line by CCNG2 overexpression. Immunohistochemistry and Western blot were used to analyze CCNG2 protein expression in colorectal cancer and to study the influence of the upregulated expression of CCNG2 that might be found on SW480 cell biological effect. We found that the level of CCNG2 protein expression was significantly lower in colorectal cancer tissue than normal tissues (P < 0.05). The level of CCNG2 was correlated with T stages, lymph node metastasis, clinic stage, and histological grade (P < 0.05). Loss of CCNG2 expression correlated significantly with poor overall survival time by Kaplan–Meier analysis (P < 0.05). The result of biological function has shown that SW480 cell-transfected CCNG2 had a lower survival fraction, higher percentage of the G0/G1 phases, and lower CDK2 protein expression compared with SW480 cell-untransfected CCNG2 (P < 0.05).
Literatur
1.
Zurück zum Zitat Bolocan A, Ion D, Ciocan DN, Paduraru DN. Prognostic and predictive factors in colorectal cancer. Chir (Bucur). 2012;107:555–63. Bolocan A, Ion D, Ciocan DN, Paduraru DN. Prognostic and predictive factors in colorectal cancer. Chir (Bucur). 2012;107:555–63.
2.
Zurück zum Zitat Dimofte G, Tarcoveanu E, Taraşi M, Panait C, Lozneanu G, Nicolescu S, et al. Mean number of lymph nodes in colonic cancer specimen: possible quality control index for surgical performance. Chir (Bucur). 2011;106:759–64. Dimofte G, Tarcoveanu E, Taraşi M, Panait C, Lozneanu G, Nicolescu S, et al. Mean number of lymph nodes in colonic cancer specimen: possible quality control index for surgical performance. Chir (Bucur). 2011;106:759–64.
3.
Zurück zum Zitat Ahmed S, Al-Saigh S, Matthews J. FOXA1 is essential for aryl hydrocarbon receptor-dependent regulation of cyclin G2. Mol Cancer Res. 2012;10:636–48.PubMedCrossRef Ahmed S, Al-Saigh S, Matthews J. FOXA1 is essential for aryl hydrocarbon receptor-dependent regulation of cyclin G2. Mol Cancer Res. 2012;10:636–48.PubMedCrossRef
4.
Zurück zum Zitat Bates S, Rowan S, Vousden KH. Characterization of human cyclin G1 and G2: DNA damage inducible genes. Oneogene. 1996;13:1103–9. Bates S, Rowan S, Vousden KH. Characterization of human cyclin G1 and G2: DNA damage inducible genes. Oneogene. 1996;13:1103–9.
5.
Zurück zum Zitat Horne MC, Goolsby GL, Donaldson KL, Tran D, Neubauer M, Wahl AF. Cyclin G1 and cyclinG2 comprise a new family of cyclins with contrasting cycle-regulated expression. J Biol Chem. 1996;271:6050–61.PubMedCrossRef Horne MC, Goolsby GL, Donaldson KL, Tran D, Neubauer M, Wahl AF. Cyclin G1 and cyclinG2 comprise a new family of cyclins with contrasting cycle-regulated expression. J Biol Chem. 1996;271:6050–61.PubMedCrossRef
6.
Zurück zum Zitat Kim Y, Shintani S, Kohno Y, Zhang R, Wong DT. Cyclin G2 dysregulation in human oral cancer. Cancer Res. 2004;64:8980–6.PubMedCrossRef Kim Y, Shintani S, Kohno Y, Zhang R, Wong DT. Cyclin G2 dysregulation in human oral cancer. Cancer Res. 2004;64:8980–6.PubMedCrossRef
7.
Zurück zum Zitat Cui XF, Liu AJ, Xu ZM. Expression of Cyclin G2 and its clinical significance in laryngeal squamouse cell carcinorna. J Clin Torhinolaryngol. 2009;23:277–9. Cui XF, Liu AJ, Xu ZM. Expression of Cyclin G2 and its clinical significance in laryngeal squamouse cell carcinorna. J Clin Torhinolaryngol. 2009;23:277–9.
8.
Zurück zum Zitat Shan G, Shan SG, Zhang XB. Expression and clinical significance of cyclin G1 and cyelinG2 in transitional cell carcinoma of bladder. Chin J Histochem Cytochmistry. 2009;18:268–72. Shan G, Shan SG, Zhang XB. Expression and clinical significance of cyclin G1 and cyelinG2 in transitional cell carcinoma of bladder. Chin J Histochem Cytochmistry. 2009;18:268–72.
9.
Zurück zum Zitat Choi MG, Noh JH, An JY, Hong SK, Park SB, Baik YH, et al. Expression levels of cyclinG2, but not cyclin E, correlate with gastric progression. J Surg Res. 2009;157:168–74.PubMedCrossRef Choi MG, Noh JH, An JY, Hong SK, Park SB, Baik YH, et al. Expression levels of cyclinG2, but not cyclin E, correlate with gastric progression. J Surg Res. 2009;157:168–74.PubMedCrossRef
10.
Zurück zum Zitat Shi W, Yu KR, Wu GY, Zhang H. Expression of CCNG2 in gastric carcinorna and its relationship with prognosis. Chin J Cell Boi. 2011;33:994–7. Shi W, Yu KR, Wu GY, Zhang H. Expression of CCNG2 in gastric carcinorna and its relationship with prognosis. Chin J Cell Boi. 2011;33:994–7.
11.
Zurück zum Zitat Song YL, Hu GH. CyclinG2: correlation with head and neck neoplasms. Intl J Otolaryngol-Head Neck Surg. 2006;30:8–11. Song YL, Hu GH. CyclinG2: correlation with head and neck neoplasms. Intl J Otolaryngol-Head Neck Surg. 2006;30:8–11.
12.
Zurück zum Zitat Le XF, Arachehige-Don AS, Mao W, Horne MC, Bast Jr RC. Roles of human epidermal growth factor receptor 2, c-Jun NH2-terminal kinase, PhosPhoinositide 3-kinase, and P7056 kinase pathways in regulation of cyclinG2 expression in human breast cancer cells. Mol Cancer Ther. 2007;6:2843–57.PubMedCrossRef Le XF, Arachehige-Don AS, Mao W, Horne MC, Bast Jr RC. Roles of human epidermal growth factor receptor 2, c-Jun NH2-terminal kinase, PhosPhoinositide 3-kinase, and P7056 kinase pathways in regulation of cyclinG2 expression in human breast cancer cells. Mol Cancer Ther. 2007;6:2843–57.PubMedCrossRef
13.
Zurück zum Zitat Martinez-Gac L, Marqués M, García Z, Campanero MR, Carrera AC. Control of cyclinG2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead. Mol Cell Biol. 2004;4:2181–9.CrossRef Martinez-Gac L, Marqués M, García Z, Campanero MR, Carrera AC. Control of cyclinG2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead. Mol Cell Biol. 2004;4:2181–9.CrossRef
14.
Zurück zum Zitat Chen J, Yusuf L, Andersen HM, Fruman DA. FOXO transcription factors cooperate withδEF1 to activate growth suppressive genes in B-lymphocytes. J Immunol. 2006;76:2711–21. Chen J, Yusuf L, Andersen HM, Fruman DA. FOXO transcription factors cooperate withδEF1 to activate growth suppressive genes in B-lymphocytes. J Immunol. 2006;76:2711–21.
15.
Zurück zum Zitat Xu G, Bernaudo S, Fu G, Lee DY, Yang BB, Peng C. CyclinG2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7. Mol Biol Cell. 2008;9:4968–79.CrossRef Xu G, Bernaudo S, Fu G, Lee DY, Yang BB, Peng C. CyclinG2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7. Mol Biol Cell. 2008;9:4968–79.CrossRef
16.
Zurück zum Zitat Cellai C, Laurenzana A, Bianchi E, Sdelci S, Manfredini R, Vannucchi AM, et al. Mechanistic insight intoWEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. Exp Hematol. 2009;7:1176–85.CrossRef Cellai C, Laurenzana A, Bianchi E, Sdelci S, Manfredini R, Vannucchi AM, et al. Mechanistic insight intoWEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. Exp Hematol. 2009;7:1176–85.CrossRef
17.
Zurück zum Zitat van Duijn PW, Ziel-van der Made AC, van der Korput JA, Trapman J. PTEN-mediated Gl cell-cycle arrest in LNCaP prostate cancer cells is associated with altered expression of cell-cycle regulators. Prostate. 2010;70:135–46.PubMed van Duijn PW, Ziel-van der Made AC, van der Korput JA, Trapman J. PTEN-mediated Gl cell-cycle arrest in LNCaP prostate cancer cells is associated with altered expression of cell-cycle regulators. Prostate. 2010;70:135–46.PubMed
18.
Zurück zum Zitat Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, Hell JW, et al. Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. J Biol Chem. 1997;272:12650–61.PubMedCrossRef Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, Hell JW, et al. Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. J Biol Chem. 1997;272:12650–61.PubMedCrossRef
19.
Zurück zum Zitat Bennin DA, Don AS, Brake T, McKenzie JL, Rosenbaum H, Ortiz L, et al. Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B' subunits in active complexes and induces nuclear aberrations and a Gl/S phase cell cycle arrst. J Biol Chem. 2002;2779:27449–67.CrossRef Bennin DA, Don AS, Brake T, McKenzie JL, Rosenbaum H, Ortiz L, et al. Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B' subunits in active complexes and induces nuclear aberrations and a Gl/S phase cell cycle arrst. J Biol Chem. 2002;2779:27449–67.CrossRef
20.
Zurück zum Zitat Arachchige Don AS, Dallapiazza RF, Bennin DA, Brake T, Cowan CE, Horne MC. CyclinG2 is a centrosome-associated nucleocytoplasmic shuttling protein that influences microtubule stability and induces a P53-dependent cell cycle arrest. Exp Cell Res. 2006;312:4181–204.PubMedCentralPubMedCrossRef Arachchige Don AS, Dallapiazza RF, Bennin DA, Brake T, Cowan CE, Horne MC. CyclinG2 is a centrosome-associated nucleocytoplasmic shuttling protein that influences microtubule stability and induces a P53-dependent cell cycle arrest. Exp Cell Res. 2006;312:4181–204.PubMedCentralPubMedCrossRef
Metadaten
Titel
CCNG2 expression is downregulated in colorectal carcinoma and its clinical significance
verfasst von
G. G. Sun
J. Zhang
W. N. Hu
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1440-5

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.